Delex Through the Years

The pioneer, supported by a regulatory pharmacist and two sales representatives, conquered the arena of the pharmaceutical industry on JULY 13, 2009. The year was a breakthrough for DPI to operate with its mother company, which is one of the fastest-growing distribution companies in the country, namely Globo Asiatico Enterprises, Inc.

The first two main products which were instrumental to DPI’s success, both promoted in GMA and Luzon, were Buminate (Albumin 25%) of Baxter Philippines (Commercial) and Tramadol (Milador) Inj. of Sandoz Philippines. These two distributors are among the most recognized pharmaceutical companies worldwide.

The company signed a distribution agreement with leading international pharmaceutical companies from South East Asia, South Asia, and even the US. These are United Biotech, India, ICU Medical Inc. (USA), and Innogene Kalbiotech, now Kalbe (Indonesia).

Delex Pharma International Inc. expanded its team from three (3) to nineteen (19) accomplished employees in 2010 as it continues to excel in the industry.

Although DPI was new, it did not hinder the company from having another impressive milestone. It engaged in Marketing Agreements with well-known national and multinational companies. Since the company provided a caliber performance, Astellas Pharma of Tokyo, Japan invested in the distribution of its original (Nicardipine) Perdipine product. With the tactical marketing of DPI, these products had overtaken the spotlight of its competitors in the market.

Before the closure of Baxter Philippines (Commercial) in the country in 2013, it entrusted DPI to market its critical care products, namely Flexbumin (Human Albumin), Premixed Potassium Chloride, and Premixed Dopamine. These products were introduced successfully to their niche market with the expertise of Delex Pharma International, Inc.

This year, the company also helped promote the Sublimaze of Janssen Pharmaceutical (Johnson & Johnson), which is the innovator brand of Fentanyl Citrate. Hence, the product re-emerged in the market with the extensive experience of Delex Pharma in marketing anesthesia and analgesia.

Proudly in the same year, the company again showcased its proven potential in contributing success to its partners. DPI had signed a distribution agreement with Innogene Kalbiotech to market Totilac™ (Hypertonic Sodium Lactate). Prior to Delex Pharma's distribution, the product has very low historical sales with only 37 bags sold in two years. However, the sales had exponentially grown with 5,500 bags sold in the first year of DPI's strategic marketing of the brand in 2010.

Undoubtedly, the success of the company for the past two years brought another deserving event as they introduced their product lines in 2011. These were Norepinephrine (Norepin®) in three (3) SKUs, 2ml, 4ml & 10ml, and Dobutamine (Dobulex). Moreover, Norepin® is among the most trusted generic norepinephrine brands in the Philippine market.

The company’s force, which was shaped by professionals, had built up reliability and confidence in supplying quality critical care products to hospitals, and business partners nationwide. Hence, this had led DPI from continuously holding its reputable name higher.

In 2012, DPI recommences what unfolded in the beginning, as it signed a Distribution Agreement with MD Pharma, providing various quality pharmaceutical products. The company had also organized a Trade Sales Division to reinforce its nationwide services in hospitals and drugstore accounts.

Customer relations are at the heart of Delex Pharma International Inc. Thus, DPI made sure that they can independently maneuver the distribution services to refine access to different channels. This calculated method directly served the satisfaction of clients and ensured that the products were promptly available, especially in critical times. Additionally, the company had continuously improved its business operations by integrating SAP  ERP applications for the management of internal business processes for effective data processing and information flow across DPI.

With a greater purpose, DLX Holdings, Inc. and High Everest Capital, Inc. acquired DPI from its mother company, Globo Asiatico. It was also the year when DPI moved to a new office at 189 Mindanao Avenue, Barangay Bahay Toro, Quezon City.

In 2013, the company sustained the momentum of skyrocketing in the field as it ventured into the anti-infective business. It launched its first two antibiotic products, Ceftazin (Ceftazidime) and Ceftrex (Ceftriaxone) manufactured by United Biotech India Pvt. Ltd.

DPI continued to broaden its horizon and applied a concept-selling marketing strategy as it initiated the promotion of Ifimol IV (Paracetamol) in 1g vial (premixed, water-based) aimed to transition from ampoule usage.

The company did not stop in extending its ability in product line distributions to aggregate its Anesthesia/Analgesia portfolio. It kicked off the marketing of Lexofol (Propofol) from Ambica International Corporation. Lexofol is one of the few Propofol brands in the market available in vial preparation.

Part of the company’s persistence in delivering notable accomplishments is the engagement of home-grown managers in enhancing their communication and leadership skills by partnering with Toastmasters International. It is a non-profit organization that teaches public speaking and leadership skills across a worldwide network of clubs.

Along its way, DPI had incorporated the Total Quality Management (TQM) Program. It aims to align the employees to be committed to maintaining high standards of work in every aspect of the company's internal policies and operations.

In 2014, DPI widened its partnerships with several companies, which proved the company’s potential in breaking through the pharmaceutical industry.

It had steadily augmented its business line and acquired dispensation of Midazolex to provide Anesthesiologists an alternative Midazolam I.V./I.M. The product is from Myungmoon Pharm, Korea.

The company had also debuted the supply of TEGO of ICU Medical, Inc., which is the first and only needle-free connector US FDA-approved for use in hemodialysis to augment the device business. Also, it initiated the next wave launch of antibiotic products, namely Spectrax (Cefipime) and Bacimycin (Clindamycin) of Claris Lifesciences. It is a company dealing in Specialty Injectable business. Sandoz Philippines Corporation had as well come to an agreement with DPI to market their generic brand of Fentanyl patch (Fendermal).

The company had again expanded its distribution channel as a corporate liaison to the biggest drugstore chain in the country, Mercury Drug Corporation. It aims to reach the branches near hospitals and nationwide.

In the same year, Delex Pharma International, Inc. had appointed the top 5 auditing firm worldwide, PwC, as an external auditor. It is designated to further build structure and control in the company’s finances based on international standards. Having PWC improves the internal systems, provides credibility, and gives shareholders confidence in the company, making the business more efficient and less prone to fraud or error.

Along with empowering its employees, the organization willingly embraced Corporate Social Responsibility. Aside from the goal of increasing sales and driving customer loyalty, we are beyond making a difference in local communities through our CSR programs to help the less fortunate Filipinos. DPI sponsored the education of 50 indigent children and increased to 125 in 2021. This program is in partnership with World Vision, a global humanitarian organization dedicated to improving people’s lives to overcome poverty. 

The institution increased its number of competent employees, along with its growing business. In 2015, Delex Pharma purchased a 360-square meter property in Brgy. Sauyo, Quezon City, became the new home of its workforce.

Furthermore, DPI wanted to raise its standards beyond excellence and to envision leadership among its employees. Thus, it established Delex University and formed a partnership with San Beda College for an on-site MBA program. 

The company had equally strengthened its IT infrastructure, as it is beneficial to respond to the growing need of the company for an enhanced information management system.

The success of the organization from the previous years had brought another partnership done with Smiths Medical, Inc., a leading global manufacturer of specialty medical devices. Delex Pharma had promoted ambulatory infusion pumps (CADD Legacy PCA & its consumables) to supplement the hospital device business. More so, Delex appointed RBC-MDC distribution company to focus efforts on marketing, inventory optimization, and in-housing its product lines and brands.

In 2016, the Marketing Department instituted the ICU Forum Program for Medical Doctors which signifies the company’s commitment to providing Continuing Medical Education (CME) support to Health Care providers. The company also founded the Spiritual Holistic Integrated Empowered Leaders of Delex (SHIELD) program, which is led by its Director, Fr. Gil Peter Coching. The program is for acculturation and values formation that empowers relevant skills and spiritual values among the young workforce.

Delex Pharma primarily focused on marketing advanced businesses in Critical Care, Anesthesia/Analgesia, and Medical devices. Then sooner, it gained a jumpstart in housing all the brands that they have been promoting only for the past six years while besting the challenges.

In the same year, DPI took over from RBC-MDC Distribution Company the distribution of its product. It aimed to develop well-maintained customer reach and service to deliver satisfaction in responding to the needs of its customers.

Meanwhile, the fifty (50) indigent scholars, which were responsibly shouldered by DPI, increased to eighty (80) pupils.

2017 was a blast for DPI after receiving various awards, which were the consequences of the brilliant steps they have endeavored. The organization received awards from Asia CEO – Executive Leadership Team of the Year and SME Company of the Year. With the attested impact on its partners, the company placed fifth (5th) in the hospital channel based on the IQVIA report.

This year was another milestone for the organization when it established two more banner brands— Nicardilex (Nicardipine) & Funginil (Fluconazole) to go with the Critical Care Franchise.

Furthermore, the powerhouse of Delex Pharma grew to one hundred eighty (180) adept and experienced employees to serve its expanding network.

Meanwhile, DPI rented a 425 square meter property in Valenzuela to house its products and its delivery operations.

Digital modification is advancing in all aspects of the business, and the workforce is no exception. With this, DPI rode along with the technological advancement providing an iPad to the sales force, which enhanced the implementation of SalesForce Effectiveness or SFE. Moreover, the firm allied with E-science Corporation for pocket-wise systems applications to improve customer reach. It improves the company’s internal process of monitoring sales and transactions automatically and generates sales reports in real-time. Hence, all data are automatically synchronized. 

In 2018, Delex Pharma continued to a headway as it initiated the innovator brand Ibuprofen I.V., (Intrafen), and the first branded generic Linezolid (Axazolid). It was also the period when it was certified by PRC as a Continuing Professional Development or CPD provider. More so, the implementation of the first ICU Forum for pharmacists took place.

The organization never ceased in hastening the skills of its employees. DPI launched a Master Class Program of Delex University to provide Leadership and Marketing training for Middle and Senior Managers. It is under the coaching of Prof. Dominador “Ringo” Gamboa from San Beda Graduate School.

Along with the efforts made this year is the institutionalization of its Corporate Social Responsibility or CSR Programs. Also, the original fifty (50) indigent scholars the company has been supporting ballooned to one hundred (100).

Delex Pharma International, Inc. persistently scaled up its performance and network until it reached its significant tenth (10th) anniversary in 2019!

DPI continued with its program in nurturing the Health Care Providers in the country. It implemented the first Joint ICU Forum for Nurses and Pharmacists in collaboration with Critical Care Medicine of the Philippine Heart Center. Moreover, it increased the number of ICU Forum Faculty as a backbone to strengthen its goal.

Continuous learning is embedded in the heart of the organization to cope with the fast-evolving environment and rapid advancement of businesses. In line with this, it launched a Mandarin Class for Management Teams to support the vision of future business expansion. It also partnered with Life Enhancement Consultancy to advance the HR program for Organizational Development and to reinforce marketing initiatives.

While technology delivers accuracy in a lot of aspects, DPI launched Mobile Dosage Calculator App for Norepin (Norepinephrine), Dobulex (Dobutamine), and Nicardilex (Nicardipine Hydrochloride). The app is downloadable from the ICU Forum website.

It was also during this notable year when CMO Asia recognized Delex Pharma International Inc. DPI took home the PHILIPPINES BEST BRAND Award 2019. Likewise, the VP for Marketing, Ms. Lourdes Monasterio, proudly received the PHILIPPINES WOMEN LEADERS Award 2019.